Literature DB >> 1371030

Activation of human immunodeficiency virus type 1 provirus in T-cells and macrophages is associated with induction of inducer-specific NF-kappa B binding proteins.

J Vlach1, P M Pitha.   

Abstract

We have analyzed the limiting factors involved in the induction of human immunodeficiency virus type 1 (HIV-1) provirus expression by tumor necrosis factor-alpha (TNF-alpha), phorbol-12-myristate-13-acetate (PMA), and bryostatin-1 in T-cells (ACH-2) and monocytes (U1). We have demonstrated that, while there is a correlation among the increase of 9.2-kilodalton (kDa) HIV-1 RNA, the increase of viral proteins (p24) in the cells, and the release of HIV-1 virions into the medium, there is no direct correlation between the levels of induced NF-kappa B binding proteins and the expression of HIV-1 provirus. The presence of nuclear NF-kappa B-specific proteins appears to be essential only for the initiation of viral replication, since the HIV-1 transcripts could be detected in TNF-alpha or bryostatin-1-stimulated cells also at later times postinduction, times when no NF-kappa B proteins could be detected in the nucleus. The uv crosslinking of DNA and proteins has shown that TNF-alpha, PMA, and bryostatin-1 induce different sets of NF-kappa B binding proteins with distinct kinetics of binding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371030     DOI: 10.1016/0042-6822(92)90295-z

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1.

Authors:  F Demarchi; F d'Adda di Fagagna; A Falaschi; M Giacca
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

2.  Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells.

Authors:  J Ye; R H Xu; J Taylor-Papadimitriou; P M Pitha
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

3.  In vivo footprinting analysis of constitutive and inducible protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1.

Authors:  F Demarchi; P D'Agaro; A Falaschi; M Giacca
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS).

Authors:  M Araghi-Niknam; B Liang; Z Zhang; S K Ardestani; R R Watson
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

5.  Release of human immunodeficiency virus by THP-1 cells and human macrophages is regulated by cellular adherence and activation.

Authors:  R J Shattock; J S Friedland; G E Griffin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro.

Authors:  K A Qatsha; C Rudolph; D Marmé; C Schächtele; W S May
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 7.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

8.  Shigella flexneri invasion of HeLa cells induces NF-kappa B DNA-binding activity.

Authors:  R B Dyer; C R Collaco; D W Niesel; N K Herzog
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 9.  Combined approaches for HIV cure.

Authors:  David M Margolis; Daria J Hazuda
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

10.  Differential contribution of herpes simplex virus type 1 gene products and cellular factors to the activation of human immunodeficiency virus type 1 provirus.

Authors:  J Vlach; P M Pitha
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.